17.07.04 · mol-cell-bio / signaling

NF-kB and JAK-STAT pathways: cytokine signaling and transcriptional responses

stub3 tiersLean: nonepending prereqs

Anchor (Master): Zhang, Q. et al. — Nat. Rev. Immunol. 17 (2017) 702-714; Stark, G. R. & Darnell, J. E. — Immunity 36 (2012) 503-514

Intuition Beginner

Cytokines are signaling molecules that immune cells use to communicate. When a cell detects a cytokine or a pathogen-associated signal, it needs to relay that information to the nucleus so the right genes turn on. Two pathways handle much of this work: NF-kB and JAK-STAT.

NF-kB is a transcription factor that sits idle in the cytoplasm, held captive by an inhibitor protein called IkappaB. When the right signal arrives — a bacterial component, an inflammatory cytokine, or cellular stress — a kinase complex called IKK phosphorylates IkappaB, marking it for destruction. Once IkappaB is gone, NF-kB is free to enter the nucleus and activate immune and survival genes.

JAK-STAT is a more direct route. Cytokine receptors do not have built-in kinase domains. Instead, they associate with JAK kinases on their intracellular tails. When a cytokine binds, the receptors dimerize, the JAKs phosphorylate each other and the receptor tails, and STAT proteins dock onto the phospho-tyrosines, get phosphorylated, dimerize, and walk into the nucleus as transcription factors. Signal to gene in four steps.

Visual Beginner

Picture two parallel pipes running from the cell surface to the nucleus. The left pipe is the NF-kB pathway. A signal (LPS from bacteria, or TNF-alpha from another immune cell) hits a receptor. Inside, the IKK complex wakes up, tags IkappaB with phosphate groups, and IkappaB is fed into the proteasome — the cell's recycling machine. NF-kB, now free, enters the nucleus.

The right pipe is the JAK-STAT pathway. A cytokine (interferon, interleukin) binds its receptor. JAK kinases attached to the receptor phosphorylate the receptor's tail. STAT proteins dock on, get phosphorylated, pair up into dimers, and enter the nucleus.

Both pathways converge on the same goal: turn on genes that change cell behavior. NF-kB targets include inflammatory cytokines, anti-apoptotic proteins, and cell-adhesion molecules. JAK-STAT targets include interferon-stimulated genes that establish an antiviral state.

Worked example Beginner

Trace what happens when a macrophage detects lipopolysaccharide (LPS), a component of the outer membrane of gram-negative bacteria.

Step 1. LPS binds the receptor TLR4 on the macrophage surface, with help from the co-receptor MD-2.

Step 2. TLR4 activates an intracellular signaling cascade through adapter proteins (MyD88, TRIF) that converges on the IKK complex.

Step 3. IKK phosphorylates IkappaB-alpha on two serine residues (Ser32 and Ser36). This phosphorylation creates a recognition site for an E3 ubiquitin ligase.

Step 4. The E3 ligase attaches ubiquitin chains to IkappaB-alpha, marking it for degradation by the proteasome.

Step 5. With IkappaB-alpha degraded, the NF-kB heterodimer (p50/p65) is free to enter the nucleus.

Step 6. In the nucleus, p50/p65 binds to kappaB sites in the promoter regions of target genes and activates transcription of TNF-alpha, IL-6, IL-1beta, and other inflammatory mediators.

The macrophage has converted a bacterial signal into a full inflammatory gene-expression program in minutes.

Check your understanding Beginner

Exercise (easy, multiple choice).

What is the role of IkappaB in the NF-kB pathway?

A. It phosphorylates NF-kB to activate it B. It binds NF-kB in the cytoplasm and prevents it from entering the nucleus C. It carries NF-kB into the nucleus D. It is a cytokine receptor

Hint

IkappaB is an inhibitor protein. Its name includes "I" for "inhibitor." Think about what an inhibitor of NF-kB would do.

Answer

B. It binds NF-kB in the cytoplasm and prevents it from entering the nucleus. IkappaB-alpha (the best-studied IkappaB family member) binds the NF-kB p50/p65 heterodimer, masks its nuclear localization signal, and sequesters it in the cytoplasm. Signal-induced phosphorylation of IkappaB by the IKK complex targets IkappaB for ubiquitin-dependent degradation, freeing NF-kB to enter the nucleus.

Exercise (easy, multiple choice).

How many steps separate cytokine binding from transcription factor activation in the JAK-STAT pathway?

A. One — the cytokine directly activates STATs B. Two — JAK phosphorylation of the receptor, then STAT docking and phosphorylation C. Approximately four — receptor dimerization, JAK trans-phosphorylation, STAT docking and phosphorylation, STAT dimerization and nuclear import D. More than ten — a long kinase cascade similar to MAPK

Hint

The JAK-STAT pathway is known for being unusually direct compared to other signaling cascades. Count: receptor activation, JAK action, STAT recruitment, STAT phosphorylation and dimerization.

Answer

C. Approximately four. The JAK-STAT pathway is remarkable for its brevity. Cytokine binding induces receptor dimerization (step 1), bringing associated JAK kinases together so they trans-phosphorylate each other and the receptor tails (step 2). STAT proteins dock onto phospho-tyrosines on the receptor via their SH2 domains and are phosphorylated by JAKs (step 3). Phosphorylated STATs dimerize via reciprocal SH2-phospho-tyrosine interactions and translocate to the nucleus (step 4). This directness allows a rapid transcriptional response — interferon-stimulated genes can be detected within 15-30 minutes of cytokine addition.

Exercise (easy, true/false).

If the proteasome is inhibited, NF-kB activation by TNF-alpha will be blocked because IkappaB cannot be degraded.

Hint

IkappaB degradation requires the proteasome. If the proteasome is non-functional, what happens to phosphorylated IkappaB?

Answer

True. IKK phosphorylation of IkappaB targets it for polyubiquitination by the SCF-beta-TrCP E3 ligase, but the ubiquitin-tagged IkappaB must still be degraded by the 26S proteasome to release NF-kB. Proteasome inhibitors (such as bortezomib, used in multiple myeloma therapy) block this degradation step. Phosphorylated, ubiquitinated IkappaB accumulates but remains bound to NF-kB, preventing nuclear translocation. This is one mechanism by which bortezomib suppresses NF-kB-driven survival signals in cancer cells.

Exercise (medium, numeric).

A cell has 100,000 molecules of the NF-kB p50/p65 heterodimer and 120,000 molecules of IkappaB-alpha. If 50,000 IkappaB-alpha molecules are degraded following TNF-alpha stimulation, estimate the number of free NF-kB heterodimers available for nuclear translocation. Assume IkappaB-alpha binds NF-kB 1:1 and no other IkappaB isoforms are present.

Hint

IkappaB-alpha binds NF-kB one-to-one. Start with 100,000 NF-kB bound by 100,000 of the 120,000 IkappaB-alpha molecules. After 50,000 IkappaB-alpha are degraded, how much IkappaB remains and how much NF-kB is freed?

Answer

Before stimulation: 100,000 NF-kB heterodimers are bound by 100,000 IkappaB-alpha molecules, with 20,000 IkappaB-alpha molecules free (unbound).

After 50,000 IkappaB-alpha molecules are degraded: the 70,000 remaining IkappaB-alpha molecules (120,000 - 50,000) are more than enough to bind all 100,000 NF-kB heterodimers if they could, but only 70,000 IkappaB-alpha molecules remain. So 70,000 NF-kB heterodimers are still bound, and 30,000 NF-kB heterodimers are free to enter the nucleus.

This 30,000-molecule pool of free NF-kB is the signal. In reality, the dynamics are more complex because newly synthesized IkappaB-alpha (itself an NF-kB target gene) provides negative feedback that re-captures NF-kB over time, creating a pulse of nuclear NF-kB activity lasting roughly 30-60 minutes.

Formal definition Intermediate+

The NF-kB and JAK-STAT pathways are two major signal transduction systems that relay cytokine and pathogen signals from cell-surface receptors to the nucleus, producing rapid transcriptional responses. Both pathways convert extracellular protein signals into changes in transcription factor activity, but they achieve this through distinct mechanisms.

NF-kB family: structure and regulation

The NF-kB (nuclear factor kappa-light-chain-enhancer of activated B cells) family in mammals consists of five members: p50 (NF-kB1, processed from p105), p65/RelA, c-Rel, p52 (NF-kB2, processed from p100), and RelB. These proteins share a Rel homology domain (RHD) responsible for DNA binding, dimerization, and nuclear localization. NF-kB functions as dimers, with the most common being the p50/p65 heterodimer.

NF-kB dimers are held inactive in the cytoplasm by the IkappaB (inhibitor of kappaB) family of proteins: IkappaB-alpha, IkappaB-beta, IkappaB-epsilon, and the precursor proteins p105 and p100. IkappaB proteins contain ankyrin repeat domains that bind the RHD of NF-kB, masking the nuclear localization signal and trapping the complex in the cytoplasm.

Canonical NF-kB activation

The canonical NF-kB pathway is triggered by TNF-alpha, IL-1, LPS (via TLR4), and antigen receptors (BCR, TCR). The central activation node is the I-kappa-B kinase (IKK) complex, a heterotrimer of IKK-alpha, IKK-beta, and NEMO (IKK-gamma, the regulatory subunit).

The activation sequence proceeds as follows:

Receptor proximal events. TNF-alpha binding to TNFR1 recruits TRADD, which recruits RIPK1, TRAF2, and cIAP1/2. LPS binding to TLR4 recruits MyD88 and TRIF, which recruit IRAK kinases and TRAF6. These complexes generate K63-linked polyubiquitin chains that serve as scaffolds.
TAK1 activation. The TAK1 kinase complex (TAK1 bound to TAB1, TAB2, and TAB3) is recruited to the ubiquitin scaffolds via the NZF domains of TAB2/3. TAK1 is activated by trans-phosphorylation.
IKK activation. TAK1 phosphorylates IKK-beta on the activation loop (Ser177 and Ser181 in human IKK-beta). NEMO binds polyubiquitin chains and positions the IKK complex for efficient phosphorylation by TAK1. IKK-alpha also undergoes activation loop phosphorylation, but IKK-beta is the primary driver of canonical NF-kB activation.
IkappaB phosphorylation. Active IKK phosphorylates IkappaB-alpha on Ser32 and Ser36. This dual phosphorylation creates a recognition motif for the SCF-beta-TrCP E3 ubiquitin ligase complex.
IkappaB ubiquitination and degradation. SCF-beta-TrCP catalyzes K48-linked polyubiquitination of IkappaB-alpha. The polyubiquitinated IkappaB-alpha is degraded by the 26S proteasome.
NF-kB nuclear translocation. With IkappaB degraded, the NF-kB dimer (typically p50/p65) is free to enter the nucleus, bind kappaB DNA motifs (5'-GGGRNNYYCC-3'), and activate transcription.

Non-canonical NF-kB activation

The non-canonical pathway centers on p100 processing to p52. It is activated by a subset of TNF receptor superfamily members (LT-beta-R, BAFF-R, CD40) that recruit TRAF2/3 and cIAP1/2, leading to stabilization and activation of NIK (NF-kB-inducing kinase). NIK phosphorylates IKK-alpha (not IKK-beta), which phosphorylates p100. Phosphorylated p100 is processed by the proteasome to generate p52, forming active p52/RelB dimers that regulate lymphoid organogenesis and B-cell maturation.

JAK-STAT pathway: architecture

The JAK-STAT (Janus kinase — Signal Transducer and Activator of Transcription) pathway couples cytokine receptor engagement directly to transcription factor activation. The pathway has four components:

Cytokine receptors. Type I and Type II cytokine receptors lack intrinsic kinase activity. They associate non-covalently with JAK kinases via membrane-proximal box1/box2 motifs.
JAK kinases. Four mammalian JAKs: JAK1, JAK2, JAK3, and TYK2. JAKs contain a FERM domain (mediating receptor association), a pseudokinase domain (regulatory, autoinhibitory), and a kinase domain (catalytic). Cytokine binding induces receptor dimerization, bringing two JAK molecules into proximity. The JAKs trans-phosphorylate each other on activation-loop tyrosines and then phosphorylate tyrosine residues on the receptor cytoplasmic tails.
STAT proteins. Seven mammalian STATs: STAT1, STAT2, STAT3, STAT4, STAT5a, STAT5b, and STAT6. Each STAT contains an SH2 domain, a DNA-binding domain, a coiled-coil domain, and a C-terminal transactivation domain. STATs are recruited to phospho-tyrosine motifs on the activated receptor via their SH2 domains. JAKs then phosphorylate a conserved tyrosine near the STAT C-terminus (Tyr701 in STAT1, Tyr705 in STAT3, etc.).
STAT dimerization and nuclear import. Phosphorylated STATs form parallel dimers via reciprocal SH2-phospho-tyrosine interactions. The dimers expose a nuclear localization signal and are actively imported through the nuclear pore complex by importin-alpha/beta. In the nucleus, STAT dimers bind to gamma-activated site (GAS) motifs or, in the case of type I interferon signaling, the ISGF3 complex (STAT1/STAT2/IRF9) binds to interferon-stimulated response elements (ISREs).

Kinetic considerations

The IKK-IkappaB-NF-kB module can be modeled as a conversion between two states of NF-kB: cytoplasmic (inactive, IkappaB-bound) and nuclear (active, DNA-bound). The key rate constants are:

\frac{d [ NF- κ B ] _{nuc}}{d t} = k_{import} [NF- κ B]_{free} - k_{export} [NF- κ B]_{nuc} - k_{IkBa} [IkBa_{new}] [NF- κ B]_{nuc},

where the third term represents IkappaB-alpha-mediated nuclear export. Because IkappaB-alpha is itself an NF-kB target gene, newly synthesized IkappaB-alpha enters the nucleus, binds NF-kB, and exports it back to the cytoplasm, creating an autoregulatory negative feedback loop. This feedback produces oscillations in nuclear NF-kB levels with a period of approximately 100 minutes, first predicted computationally by the Hoffman-Leverton-Baltimore model and subsequently observed experimentally using live-cell imaging of p65-GFP fusion proteins.

Key mechanism Intermediate+

Mechanism (gamma-interferon JAK-STAT signaling). Gamma-interferon (IFN-gamma) signals through a receptor composed of IFNGR1 and IFNGR2 chains. IFNGR1 is pre-associated with JAK1, and IFNGR2 with JAK2. IFN-gamma binding induces receptor dimerization, bringing JAK1 and JAK2 into proximity. Trans-phosphorylation of JAK1 (on Tyr1034/1035) and JAK2 (on Tyr1007/1008) activates both kinases. Active JAKs phosphorylate IFNGR1 on Tyr440, creating a docking site for the STAT1 SH2 domain. STAT1 is recruited, phosphorylated on Tyr701 by JAK1/JAK2, and forms a parallel homodimer via reciprocal SH2-phospho-Tyr701 interactions. The STAT1 homodimer (called GAF, gamma-activated factor) translocates to the nucleus and binds GAS (gamma-activated sequence) elements with the consensus 5'-TTCCGGAA-3', activating transcription of interferon-stimulated genes including IRF1, CIITA, and iNOS.

The specificity of JAK-STAT signaling arises from receptor-JAK pairing and STAT SH2 domain selectivity. Different cytokine receptors associate with specific JAK combinations: IFN-alpha/beta receptors use TYK2/JAK1, growth hormone receptor uses JAK2, IL-2 family receptors use JAK1/JAK3, and IL-6 family receptors use JAK1/JAK2 (or JAK1/TYK2). The STAT recruited depends on the phospho-tyrosine motifs generated on the receptor tail: STAT1 prefers Y-D-K-P-H motifs, STAT3 prefers Y-X-X-Q motifs, STAT5 prefers Y-X-X-L motifs, and STAT6 prefers Y-X-X-H motifs. This receptor code determines which STAT is activated and thus which gene expression program is triggered.

Exercises Intermediate+

Exercise 1 (easy, symbolic).

State the role of each of the following proteins in the NF-kB pathway: IKK-alpha, IKK-beta, NEMO/IKK-gamma, IkappaB-alpha, SCF-beta-TrCP.

Hint

IKK is a kinase complex. IkappaB is an inhibitor. SCF-beta-TrCP is an E3 ubiquitin ligase.

Answer

IKK-alpha: Catalytic subunit of the IKK complex. Primary role in the non-canonical NF-kB pathway (phosphorylating p100 for processing to p52). Also contributes to canonical signaling and keratinocyte differentiation.

IKK-beta: Catalytic subunit of the IKK complex. Primary driver of canonical NF-kB activation. Phosphorylated by TAK1 on the activation loop, then phosphorylates IkappaB-alpha on Ser32/Ser36. Loss of IKK-beta abolishes canonical NF-kB activation.

NEMO/IKK-gamma: Regulatory subunit of the IKK complex. Contains a coiled-coil domain, a leucine zipper, and a zinc finger. Binds K63-linked and linear polyubiquitin chains via its UBAN and zinc finger domains, recruiting the IKK complex to activated receptor signaling complexes. NEMO is essential for IKK activation — NEMO knockout is embryonic lethal.

IkappaB-alpha: Inhibitor protein that binds the NF-kB p50/p65 heterodimer, masks its nuclear localization signal, and retains it in the cytoplasm. Phosphorylated by IKK on Ser32/Ser36, targeting it for SCF-beta-TrCP-mediated ubiquitination and proteasomal degradation. An NF-kB target gene, creating a negative feedback loop.

SCF-beta-TrCP: E3 ubiquitin ligase complex (Skp1-Cul1-F-box protein with the F-box protein beta-TrCP). Recognizes the doubly phosphorylated degron motif (DSGLDS) on IkappaB-alpha and catalyzes K48-linked polyubiquitination, targeting IkappaB-alpha for proteasomal degradation.

Exercise 2 (easy, symbolic).

Name the four mammalian JAK kinases and the seven mammalian STAT proteins. For each JAK, name one cytokine receptor that requires it.

Hint

JAK1, JAK2, JAK3, and TYK2. STATs are numbered 1 through 6, with STAT5 split into STAT5a and STAT5b. Think about which receptors are affected by JAK-specific loss-of-function mutations.

Answer

JAK kinases:

JAK1: Associates with IFNGR1 (gamma-interferon receptor), IL-6 receptor family, and IL-2 receptor family. JAK1 loss-of-function causes severe combined immunodeficiency.
JAK2: Associates with IFNGR2, growth hormone receptor, erythropoietin receptor, thrombopoietin receptor, and G-CSF receptor. JAK2 V617F is the driver mutation in most myeloproliferative neoplasms.
JAK3: Associates exclusively with the common gamma-chain (gamma-c) shared by IL-2, IL-4, IL-7, IL-9, IL-15, and IL-21 receptors. JAK3 deficiency causes SCID.
TYK2: Associates with IFNAR1 (type I interferon receptor), IL-12 receptor, and IL-23 receptor.

STAT proteins:

STAT1, STAT2, STAT3, STAT4, STAT5a, STAT5b, and STAT6. STAT1 mediates interferon responses (antiviral, antimicrobial). STAT2 forms the ISGF3 complex with STAT1 and IRF9. STAT3 drives acute-phase response and is frequently constitutively active in cancer. STAT4 mediates IL-12 signaling in Th1 differentiation. STAT5a/5b mediate prolactin and growth hormone signaling. STAT6 mediates IL-4/IL-13 signaling in Th2 differentiation and allergic responses.

Exercise 3 (medium, symbolic).

Compare the canonical and non-canonical NF-kB pathways in terms of activating signals, the IKK subunits involved, the IkappaB-like substrate, the NF-kB dimer produced, and the biological processes controlled.

Hint

Canonical uses IKK-beta (with NEMO) and degrades IkappaB-alpha. Non-canonical uses IKK-alpha (with NIK) and processes p100 to p52.

Answer

Canonical NF-kB:

Activating signals: TNF-alpha, IL-1, LPS/TLR4, antigen receptors (BCR, TCR), dsRNA, cellular stress.
IKK subunits: IKK-beta (catalytic) and NEMO (regulatory). IKK-alpha is present but dispensable.
Substrate: IkappaB-alpha, -beta, -epsilon. Phosphorylated by IKK-beta on two N-terminal serines, ubiquitinated by SCF-beta-TrCP, degraded by the proteasome.
NF-kB dimer: Primarily p50/p65 and p50/c-Rel.
Biological processes: Rapid inflammatory response, innate immunity, anti-apoptosis, cell survival. Activated within minutes.

Non-canonical NF-kB:

Activating signals: LT-beta, BAFF, CD40L, RANKL, TNF-like weak inducer of apoptosis (TWEAK).
IKK subunits: IKK-alpha (catalytic), activated by NIK. NEMO and IKK-beta are not required.
Substrate: p100 (NF-kB2 precursor). Phosphorylated by IKK-alpha on the C-terminal degron, leading to partial proteasomal processing to p52.
NF-kB dimer: p52/RelB.
Biological processes: Lymphoid organogenesis (lymph node, Peyer's patch development), B-cell maturation and survival, bone metabolism. Activated over hours.

The two pathways are genetically separable: IKK-beta knockout abolishes canonical but spares non-canonical signaling, while IKK-alpha knockout or NIK knockout abolishes non-canonical but spares canonical signaling.

Exercise 4 (medium, symbolic).

SOCS (suppressor of cytokine signaling) proteins are induced by JAK-STAT signaling and inhibit the pathway. Describe three mechanisms by which SOCS proteins attenuate JAK-STAT signaling, and explain why this creates a negative feedback loop.

Hint

SOCS proteins contain a SH2 domain (which can bind phospho-tyrosines) and a SOCS box (which recruits E3 ubiquitin ligase complexes). Think about what each domain could do.

Answer

SOCS proteins (SOCS1-7 and CIS) attenuate JAK-STAT signaling through three mechanisms:

Kinase inhibition via the KIR domain. SOCS1 and SOCS3 contain a kinase inhibitory region (KIR) that directly binds the JAK kinase domain, blocking substrate access. SOCS1 binds the JAK1, JAK2, and TYK2 activation loops with high affinity. SOCS3 lacks a strong KIR but inhibits JAKs indirectly by binding phospho-tyrosine motifs on the receptor.
Competition for phospho-tyrosine docking sites. The SH2 domain of SOCS proteins competes with STAT SH2 domains for binding to phospho-tyrosine motifs on activated cytokine receptors. By occupying these sites, SOCS proteins prevent STAT recruitment and phosphorylation.
Ubiquitin-mediated degradation via the SOCS box. The SOCS box domain recruits elongin B/C, cullin 5, and Rbx2 to form an E3 ubiquitin ligase complex. This complex catalyzes K48-linked polyubiquitination of bound JAKs or receptors, targeting them for proteasomal degradation.

This creates a negative feedback loop because SOCS genes are themselves STAT target genes. When JAK-STAT signaling is active, STAT dimers in the nucleus activate SOCS transcription. Newly synthesized SOCS proteins inhibit further JAK-STAT signaling, creating a pulse of STAT activity that decays as SOCS protein accumulates. The dynamics produce transient STAT activation (peaking at 15-30 minutes, returning to baseline by 2-4 hours) rather than sustained signaling.

Exercise 5 (hard, symbolic).

The IkappaB-alpha-NF-kB negative feedback loop can produce oscillations in nuclear NF-kB concentration. Describe the mechanism producing these oscillations, estimate the period, and explain why the oscillation requires both a delay (new IkappaB-alpha synthesis) and a nonlinearity (cooperative IkappaB binding or IKK regulation).

Hint

NF-kB activates IkappaB-alpha transcription. IkappaB-alpha protein binds nuclear NF-kB and exports it. What happens when there is a delay between NF-kB activation and new IkappaB-alpha protein appearing?

Answer

The oscillation mechanism proceeds as follows:

A stimulus activates IKK, which phosphorylates and degrades existing IkappaB-alpha. NF-kB (p50/p65) translocates to the nucleus and activates target genes including IkappaB-alpha.
There is a delay of approximately 20-30 minutes between NF-kB nuclear entry and accumulation of newly translated IkappaB-alpha protein. During this delay, NF-kB remains nuclear and active.
Newly synthesized IkappaB-alpha enters the nucleus, binds NF-kB, and exports it back to the cytoplasm. Nuclear NF-kB levels drop.
With NF-kB out of the nucleus, IkappaB-alpha transcription ceases. Existing IkappaB-alpha protein has a half-life of approximately 30-60 minutes under basal conditions and is degraded. IKK may still be active (depending on stimulus duration), so it phosphorylates the newly synthesized IkappaB-alpha bound to NF-kB.
This frees NF-kB again, producing a second pulse of nuclear translocation.

The oscillation period is approximately 100 minutes (roughly the sum of the transcriptional/translational delay plus the IkappaB-alpha turnover time), matching experimental measurements in single-cell imaging studies (Nelson et al., Science 2004).

The oscillation requires two ingredients. First, a delay: if IkappaB-alpha appeared instantaneously, NF-kB would be recaptured immediately and no pulse would form. The transcriptional-translational delay of 20-30 minutes allows NF-kB to accumulate in the nucleus before being recaptured. Second, a nonlinearity: the IKK-IkappaB-NF-kB module must be nonlinear for oscillation. This nonlinearity comes from cooperative IKK activation kinetics and from the multi-step process of IkappaB-alpha degradation (IKK phosphorylation, ubiquitination, proteasomal processing). Without nonlinearity, the negative feedback produces damped approach to steady state rather than sustained oscillation.

Different cell types show different oscillation characteristics: some show sustained oscillations, others show one or two pulses then decay. The number of pulses depends on stimulus strength, IKK inactivation kinetics, and the expression of other IkappaB isoforms (IkappaB-beta, IkappaB-epsilon) that provide overlapping feedback with different time constants.

Exercise 6 (hard, symbolic).

NF-kB and JAK-STAT signaling both contribute to the inflammatory gene expression program, but they are activated by overlapping yet distinct sets of stimuli. Compare and contrast: (a) the signal-to-nucleus relay speed of each pathway, (b) the breadth of target genes, (c) the feedback mechanisms, and (d) the therapeutic strategies for inhibiting each pathway in chronic inflammatory disease.

Hint

NF-kB has an IkappaB degradation step and oscillatory feedback. JAK-STAT is more direct but uses SOCS feedback. Think about kinase inhibitors and proteasome inhibitors.

Answer

(a) Signal-to-nucleus relay speed. The JAK-STAT pathway is faster. Cytokine binding to STAT phosphorylation takes approximately 5-15 minutes, and STAT dimers appear in the nucleus within 15-30 minutes. NF-kB activation requires IKK activation, IkappaB phosphorylation, ubiquitination, and proteasomal degradation before NF-kB can translocate. This takes approximately 15-30 minutes. However, NF-kB's oscillatory dynamics mean the response persists in pulses, while JAK-STAT typically shows a single pulse that decays due to SOCS feedback.

(b) Breadth of target genes. NF-kB has a broader target spectrum. The p50/p65 heterodimer binds thousands of genomic sites and regulates hundreds of genes spanning inflammatory cytokines, chemokines, anti-apoptotic proteins (Bcl-2, Bcl-xL, XIAP), cell adhesion molecules (ICAM-1, VCAM-1), and additional signaling molecules. JAK-STAT target genes are more pathway-specific: STAT1 targets are primarily antiviral and antimicrobial genes, STAT3 targets include acute-phase proteins and survival factors, and STAT6 targets drive Th2/allergic responses. NF-kB functions as a hub integrating diverse stress signals; JAK-STAT pathways function as parallel channels with defined cytokine inputs.

(c) Feedback mechanisms. NF-kB uses transcriptional negative feedback (IkappaB-alpha resynthesis) that creates oscillations. Additional feedback includes A20 (a deubiquitinase that removes activating ubiquitin chains from TRAF6 and RIPK1) and CYLD. JAK-STAT uses SOCS protein feedback (transcriptional induction followed by JAK inhibition, receptor competition, and ubiquitin-mediated degradation). Both feedback systems are transcriptionally induced by their respective pathways, but NF-kB feedback is primarily at the level of transcription factor sequestration, while SOCS feedback is at the level of kinase and receptor inhibition.

(d) Therapeutic strategies. NF-kB pathway inhibition strategies include: proteasome inhibitors (bortezomib, which prevents IkappaB degradation), IKK inhibitors (BMS-345541 and others in development), and upstream blockade with TNF-alpha antibodies (infliximab, adalimumab) or TNF receptors (etanercept). Direct NF-kB DNA-binding inhibitors have proven difficult to develop. JAK-STAT inhibition is more advanced clinically: JAK inhibitors (tofacitinib/JAK1/3, ruxolitinib/JAK1/2, baricitinib/JAK1/2, upadacitinib/JAK1) are approved for rheumatoid arthritis, myelofibrosis, psoriatic arthritis, and atopic dermatitis. The druggability difference reflects the kinase-centric nature of JAK-STAT versus the protein-protein interaction and ubiquitin-dependent mechanisms in NF-kB signaling.

NF-kB in chronic inflammation, cancer, and therapeutic targeting Master

NF-kB was first identified in 1986 by Ranjan Sen and David Baltimore as a nuclear factor binding to the kappa immunoglobulin light-chain enhancer in B cells. What began as a B-cell-specific transcription factor proved to be a central regulator of immune and inflammatory responses in virtually all cell types, and one of the most consequential signaling pathways in human disease.

Canonical NF-kB in inflammation

The canonical NF-kB pathway is the master transcriptional regulator of the inflammatory response. LPS activation through TLR4, TNF-alpha through TNFR1, and IL-1 through IL-1R all converge on the IKK complex. The resulting nuclear NF-kB activates a stereotyped gene expression program: pro-inflammatory cytokines (TNF-alpha, IL-1beta, IL-6), chemokines (IL-8/CXCL8, MCP-1/CCL2), adhesion molecules (ICAM-1, VCAM-1, E-selectin), anti-apoptotic factors (Bcl-2, Bcl-xL, c-FLIP, XIAP), and enzymes (COX-2, iNOS). This program recruits immune cells to the site of infection, activates them, and prevents their death during the inflammatory response.

In acute inflammation, NF-kB activation is transient and self-limiting. The IkappaB-alpha negative feedback loop, A20 deubiquitinase induction, and phosphatase-mediated IKK inactivation all contribute to signal termination. Chronic inflammation arises when NF-kB activation becomes sustained, producing a tissue-destructive positive feedback loop in which NF-kB-driven TNF-alpha and IL-1 activate NF-kB in neighboring cells, which produce more TNF-alpha and IL-1.

This feed-forward amplification underlies rheumatoid arthritis (synovial fibroblast NF-kB activation), inflammatory bowel disease (intestinal epithelial and macrophage NF-kB activation), atherosclerosis (vascular endothelial and macrophage NF-kB activation in the arterial wall), and chronic obstructive pulmonary disease. The clinical success of TNF-alpha blockers (infliximab, adalimumab, etanercept) validates NF-kB pathway blockade at the upstream cytokine level, but these agents only block one activating input. Direct IKK inhibitors would block all canonical NF-kB inputs simultaneously but have encountered toxicity challenges because NF-kB is also required for tissue homeostasis and immune defense.

NF-kB in cancer

NF-kB contributes to cancer through several mechanisms:

Anti-apoptotic signaling. NF-kB upregulates Bcl-2, Bcl-xL, c-FLIP (which inhibits caspase-8), XIAP, and survivin. Tumors with constitutive NF-kB activity resist chemotherapy-induced apoptosis.
Proliferative signaling. NF-kB activates cyclin D1 transcription and induces growth factors (IL-6, VEGF) that act in autocrine and paracrine loops. In diffuse large B-cell lymphoma (DLBCL), the activated B-cell (ABC) subtype depends on chronic active BCR signaling that sustains NF-kB through CARD11-BCL10-MALT1 complex assembly.
Angiogenesis and invasion. NF-kB induces VEGF, IL-8, and MMP-9, promoting angiogenesis and extracellular matrix degradation.
Inflammation-driven tumorigenesis. Colitis-associated cancer, hepatitis-associated hepatocellular carcinoma, and gastritis-associated gastric cancer all feature chronic NF-kB activation in the inflamed tissue. Mouse models show that IKK-beta deletion in intestinal epithelial cells reduces colitis-associated tumor incidence by 80%, while deletion in myeloid cells reduces tumor size, demonstrating that NF-kB drives tumor initiation from epithelial cells and tumor promotion from inflammatory cells.
Tumor microenvironment. NF-kB in tumor-associated macrophages drives an immunosuppressive secretome (IL-10, TGF-beta, arginase-1) that inhibits cytotoxic T-cell function. NF-kB-mediated PD-L1 upregulation on tumor cells contributes to immune checkpoint engagement.

Therapeutic targeting

The NF-kB pathway has proven challenging to drug directly. The transcription factor itself is not an enzyme and has no obvious small-molecule binding pocket. Therapeutic approaches have instead targeted upstream components:

Proteasome inhibitors. Bortezomib (Velcade) blocks the 26S proteasome, preventing IkappaB degradation and NF-kB activation. Approved for multiple myeloma and mantle cell lymphoma. The mechanism of action is broader than NF-kB inhibition alone — proteasome inhibition also causes ER stress, disrupts protein homeostasis, and activates the unfolded protein response, all contributing to anti-myeloma activity.
IKK inhibitors. Multiple IKK-beta inhibitors have entered clinical development (BMS-345541, MLN120B, TPCA-1), but none has been approved. The challenges include hepatotoxicity (NF-kB is hepatoprotective), immunosuppression (NF-kB is required for innate and adaptive immune responses), and the feedback between NF-kB and other pathways.
Upstream cytokine blockade. TNF-alpha inhibitors (infliximab, adalimumab, etanercept, certolizumab) are approved for rheumatoid arthritis, Crohn's disease, psoriasis, and ankylosing spondylitis. IL-1 inhibitors (anakinra, canakinumab) are approved for rheumatoid arthritis, cryopyrin-associated periodic syndromes, and other autoinflammatory conditions. These agents block specific upstream activators without globally suppressing NF-kB.
NEMO-binding domain peptides. The NEMO-binding domain (NBD) peptide disrupts the IKK-beta-NEMO interaction, selectively blocking canonical NF-kB activation. Preclinical studies show efficacy in arthritis and colitis models, but peptide delivery remains a challenge.

IL-6 trans-signaling

IL-6 signals through two mechanisms. Classic signaling uses membrane-bound IL-6R (expressed on hepatocytes and some immune cells). Trans-signaling uses soluble IL-6R (sIL-6R), which complexes with IL-6 and activates gp130 on any cell type. Trans-signaling is the pathological mode: it drives chronic inflammation, endothelial activation, and tumor cell proliferation. Olamkicept (sgp130Fc), a decoy gp130 that selectively blocks IL-6 trans-signaling while sparing classic signaling, has shown efficacy in clinical trials for inflammatory bowel disease.

STAT3 is the primary mediator of IL-6 signaling in cancer. Persistent STAT3 activation (driven by autocrine IL-6 loops, gain-of-function mutations in JAK2 or STAT3, or loss of SOCS3) promotes proliferation, survival, angiogenesis, and immune evasion. STAT3 is constitutively active in approximately 70% of solid tumors and is considered an oncogenic transcription factor, although direct STAT3 inhibitors have proven difficult to develop because STAT3's DNA-binding surface and SH2-phospho-tyrosine interface are challenging drug targets.

JAK-STAT in myeloproliferative neoplasms and therapeutic intervention Master

JAK2 V617F: a driver mutation

The JAK2 V617F mutation, discovered in 2005 by four independent groups, is present in approximately 95% of polycythemia vera patients, 50-60% of essential thrombocythemia patients, and 40-50% of primary myelofibrosis patients. The valine-to-phenylalanine substitution at position 617 lies in the JH2 pseudokinase domain, which normally exerts autoinhibitory control over the JH1 kinase domain. V617F disrupts this autoinhibition, producing constitutive JAK2 kinase activity and ligand-independent signaling through the erythropoietin receptor, thrombopoietin receptor (MPL), and granulocyte colony-stimulating factor receptor.

The consequence is clonal expansion of hematopoietic progenitors that no longer require normal cytokine regulation. Erythroid progenitors proliferate without erythropoietin (polycythemia vera), megakaryocytic progenitors proliferate without thrombopoietin (essential thrombocythemia), and the bone marrow develops fibrosis driven by cytokine release from the neoplastic clone (primary myelofibrosis).

Ruxolitinib and JAK inhibitor therapy

Ruxolitinib (Jakafi), a JAK1/JAK2 inhibitor approved in 2011 for myelofibrosis and 2014 for polycythemia vera, was the first targeted therapy for myeloproliferative neoplasms. It reduces splenomegaly and constitutional symptoms (fatigue, night sweats, weight loss) in myelofibrosis, and controls hematocrit in polycythemia vera patients intolerant of hydroxyurea.

Ruxolitinib does not eliminate the JAK2 V617F clone. It suppresses cytokine-driven inflammation and JAK-STAT signaling but does not produce molecular remissions. The JAK2 V617F allele burden typically decreases by only 10-20% after years of treatment. This reflects the fact that ruxolitinib is a cytostatic agent, not a cytotoxic one, and that the mutation is in a stem cell that is less dependent on JAK-STAT signaling than the differentiated progeny.

Fedratinib (JAK2-selective), pacritinib (JAK2/IRAK1), and momelotinib (JAK1/JAK2/ACVR1) have subsequently been approved, each with a distinct profile. Fedratinib carries a risk of encephalopathy (Wernicke's) from thiamine transport inhibition. Pacritinib is approved for myelofibrosis with severe thrombocytopenia. Momelotinib additionally inhibits ACVR1, reducing hepcidin expression and improving anemia.

STAT3 in cancer biology

STAT3 is the most frequently dysregulated STAT in cancer. Its canonical activation by IL-6 family cytokines, EGF, and other growth factors produces transient signaling in normal cells. In cancer, persistent STAT3 activation arises from autocrine cytokine loops (IL-6/IL-6R/gp130 autocrine circuits), loss of SOCS3 expression (by promoter methylation or deletion), gain-of-function mutations (STAT3 N647I and other activating mutations in large granular lymphocyte leukemia), or upstream kinase activation (JAK2 V617F, Src family kinase activation).

Constitutively active STAT3 drives expression of: cyclin D1 and c-Myc (proliferation), Bcl-2, Bcl-xL, Mcl-1, and survivin (survival), VEGF and bFGF (angiogenesis), and IL-10 and TGF-beta (immune suppression). STAT3 also induces regulatory T-cell recruitment and myeloid-derived suppressor cell expansion in the tumor microenvironment, creating an immunosuppressive niche that reduces the efficacy of immune checkpoint inhibitors.

Targeting STAT3 has proven difficult. The SH2 domain is the most druggable site, and several SH2-domain inhibitors have entered clinical trials (napabucasin, TTI-101, WP1066), but none has achieved regulatory approval. STAT3 decoy oligonucleotides (which compete with genomic DNA for STAT3 binding) have shown activity in head and neck cancer in phase 0 trials. Antisense oligonucleotides (AZD9150/danvatirsen) and siRNA approaches targeting STAT3 mRNA are in clinical development.

Interferon therapy

The JAK-STAT pathway was first identified through the study of interferon signaling. Type I interferons (IFN-alpha, IFN-beta) signal through the IFNAR1/IFNAR2 receptor complex, activating TYK2/JAK1, which phosphorylate STAT1 and STAT2. The STAT1/STAT2 heterodimer associates with IRF9 to form the ISGF3 complex, which binds ISREs and activates hundreds of interferon-stimulated genes (ISGs) that establish an antiviral state: MxA (inhibits viral replication), PKR (inhibits translation of viral RNAs), OAS/RNase L (degrades viral RNA), and MHC class I upregulation (enhances antigen presentation to CD8+ T cells).

Pegylated interferon-alpha (peg-IFN-alpha) has been used for decades to treat hepatitis B and C (before direct-acting antivirals for HCV), melanoma, and certain leukemias (hairy cell leukemia, chronic myeloid leukemia in the pre-imatinib era). The side effects — flu-like symptoms, depression, autoimmune reactions — reflect the broad activation of immune and inflammatory programs by IFN-alpha through JAK-STAT signaling.

Connections Master

Cell signaling: receptors and GPCRs 17.07.01. TNFR1 is a death domain-containing receptor, not a GPCR or RTK, but its signaling complex assembly shares conceptual features with GPCR signalosome formation. TLR4 uses both MyD88-dependent and TRIF-dependent signaling that converges on IKK. The receptor architecture (transmembrane, ligand-induced activation) connects to the receptor principles in 17.07.01.
RTK-MAPK signaling cascade 17.07.02. NF-kB and MAPK pathways are co-activated by many stimuli (TNF-alpha, LPS, growth factors). ERK phosphorylates and activates IkappaB-alpha in some contexts, creating pathway crosstalk. TNF-alpha simultaneously activates NF-kB (survival) and can activate apoptosis — the balance between these outcomes is modulated by NF-kB-driven anti-apoptotic gene expression. The MAPK and NF-kB pathways provide redundant survival signals in many cancers.
PI3K-Akt-mTOR pathway 17.07.03 pending. Akt can phosphorylate IKK-alpha on Thr23, directly activating the IKK complex and linking growth-factor/PI3K signaling to NF-kB. IKK-beta phosphorylates the mTOR inhibitor TSC1, connecting NF-kB to metabolic regulation. In B-cell lymphomas, the BCR signaling cascade simultaneously activates NF-kB (via CARD11-BCL10-MALT1), PI3K-Akt-mTOR, and MAPK, and effective therapy requires blocking multiple branches.
Innate immunity 17.10.01. TLR4 signaling through MyD88 to NF-kB is one of the primary innate immune activation pathways. The TRIF-dependent arm also activates IRF3 (interferon regulatory factor 3), connecting TLR4 to type I interferon production and the JAK-STAT antiviral program.
Transcription 17.05.02. NF-kB and STATs are sequence-specific transcription factors that recruit co-activators (CBP/p300, Mediator) and chromatin remodeling complexes to target gene promoters and enhancers. The transcriptional output depends on chromatin accessibility, co-factor availability, and cooperative binding with other transcription factors (NF-kB cooperates with AP-1 and IRF proteins; STATs cooperate with IRFs and AP-1).
Protein structure 17.01.02 pending. The STAT SH2 domain — a approximately 100-residue module that recognizes phospho-tyrosine in a sequence-specific context — is one of the best-characterized protein interaction domains. The IKK kinase domain, the Rel homology domain of NF-kB, and the ankyrin repeats of IkappaB are all structurally characterized at atomic resolution. The NEMO coiled-coil/leucine zipper oligomerization domain and ubiquitin-binding UBAN motif are essential for signal-dependent IKK activation.

Historical notes Master

David Baltimore and Ranjan Sen identified NF-kB in 1986 as a nuclear factor in B cells that bound the kappa immunoglobulin light-chain enhancer. The name "NF-kB" reflects this origin.
The discovery in 1991 that IkappaB-alpha retains NF-kB in the cytoplasm, and the subsequent identification of the IKK complex in 1997 by multiple groups, established the signal-dependent activation mechanism.
The IKK complex was purified and cloned in 1997-1998 by the Karin, Maniatis, and Mercurio laboratories. IKK-alpha and IKK-beta were identified as the catalytic subunits, and NEMO (IKK-gamma) was identified by DiDonato and colleagues as the essential regulatory subunit. Mutations in NEMO cause incontinentia pigmenti and immunodeficiency in humans.
The JAK-STAT pathway was discovered in 1992 by George Stark, James Darnell, and colleagues, who identified STAT1 and STAT2 as the transcription factors activated by interferon signaling. The name "STAT" (Signal Transducer and Activator of Transcription) captures the pathway's defining feature: the same protein functions as both the signal transducer (phosphorylated by JAK at the receptor) and the transcription factor (binding DNA in the nucleus).
The JAK kinases were named after Janus, the two-faced Roman god, because they contain two kinase-related domains (JH1, the active kinase, and JH2, the pseudokinase). The V617F mutation in JAK2 was discovered simultaneously by four groups in 2005 and transformed the understanding of myeloproliferative neoplasms from diseases of unknown etiology to kinase-driven cancers.
Ruxolitinib was approved by the FDA in 2011 for myelofibrosis, based on the COMFORT-I and COMFORT-II clinical trials that demonstrated spleen size reduction and symptom improvement. It was the first drug approved for myelofibrosis and validated JAK inhibition as a therapeutic strategy.
The mathematical modeling of NF-kB oscillations by Hoffmann, Levchenko, and Baltimore (2002) and the experimental observation of these oscillations by Nelson et al. (2004) using p65-GFP live-cell imaging established NF-kB as a model system for studying signaling dynamics in single cells.

Bibliography Master

Zhang, Q., Lenardo, M. J. & Baltimore, D. — 30 Years of NF-kappaB: A Blossoming of Relevance to Human Pathobiology. Nat. Rev. Immunol. 17 (2017) 702-714.
Stark, G. R. & Darnell, J. E. — The JAK-STAT Pathway at Twenty. Immunity 36 (2012) 503-514.
Hoffmann, A., Levchenko, A., Scott, M. L. & Baltimore, D. — The IkappaB-NF-kappaB Signaling Module: Temporal Control and Selective Gene Activation. Science 298 (2002) 1241-1245.
Nelson, D. E., Ihekwaba, A. E. C., Elliott, M., Johnson, J. R., Gibney, C. A., Foreman, B. E., Nelson, G., See, V., Horton, C. A., Spiller, D. G., Edwards, S. W., McDowell, H. P., Unitt, J. F., Sullivan, E., Grimley, R., Benson, N., Broomhead, D., Kell, D. B. & White, M. R. H. — Oscillations in NF-kappaB Signaling Control the Dynamics of Gene Expression. Science 306 (2004) 704-708.
Levine, R. L., Wadleigh, M., Cools, J., Ebert, B. L., Wernig, G., Huntly, B. J., Boggon, T. J., Wlodarska, I., Clark, J. J., Moore, S., Adelsperger, J., Koo, S., Lee, J. C., Gabriel, S., Mercher, T., D'Andrea, A., Frohling, S., Dohner, K., Marynen, P., Vandenberghe, P., Mesa, R. A., Tefferi, A., Griffin, J. D., Eck, M. J., Sellers, W. R., Meyerson, M., Golub, T. R., Lee, S. J. & Gilliland, D. G. — Activating Mutation in the Tyrosine Kinase JAK2 in Polycythemia Vera, Essential Thrombocythemia, and Myelofibrosis. Cancer Cell 7 (2005) 387-397.
Karin, M. & Greten, F. R. — NF-kappaB: Linking Inflammation and Immunity to Cancer Development and Progression. Nat. Rev. Immunol. 5 (2005) 749-759.
Schindler, C., Levy, D. E. & Decker, T. — JAK-STAT Signaling: From Interferons to Cytokines. J. Biol. Chem. 282 (2007) 20059-20063.
He, G. & Karin, M. — NF-kappaB and STAT3 — Key Players in Liver Inflammation and Cancer. Cell Res. 21 (2011) 159-168.
McMurray, H. R. & George, D. J. — The JAK-STAT Pathway in Myeloproliferative Neoplasms. JAK-STAT 4 (2015) e990063.
Alimonti, J. B., Ball, T. B. & Fowke, K. R. — Mechanisms of CD4+ T Lymphocyte Cell Death in HIV Infection and AIDS. J. Gen. Virol. 84 (2003) 1649-1661. (Includes NF-kB dysregulation in HIV pathogenesis.)